Access Bio, Inc. (KOSDAQ:950130)
South Korea · Delayed Price · Currency is KRW 4,660.00
+10.00 (0.22%)
Oct 10, 2025, 3:30 PM KST
Access Bio Revenue
Access Bio had revenue of 1.37B KRW in the quarter ending June 30, 2025, a decrease of -94.52%. This brings the company's revenue in the last twelve months to 74.42B, down -25.62% year-over-year. In the year 2024, Access Bio had annual revenue of 112.46B, down -67.74%.
Revenue (ttm)
74.42B
Revenue Growth
-25.62%
P/S Ratio
2.20
Revenue / Employee
736.85M
Employees
101
Market Cap
163.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112.46B | -236.18B | -67.74% |
| Dec 31, 2023 | 348.64B | -685.22B | -66.28% |
| Dec 31, 2022 | 1,033.86B | 528.75B | 104.68% |
| Dec 31, 2021 | 505.11B | 383.31B | 314.71% |
| Dec 31, 2020 | 121.80B | 78.74B | 182.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| LigaChem Biosciences | 148.28B |